When do biologic drug patents expire and when will biosimilars launch?

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,905,979

Introduction

United States Patent 8,905,979 (hereafter "the '979 patent") represents a significant intellectual property asset within the pharmaceutical or biotech domain, depending on its respective claims and filed technologies. This patent, issued on December 9, 2014, exemplifies innovative efforts in its field, likely covering novel compounds, formulations, or methods. A critical evaluation of its claims, scope, and landscape context provides essential insight into its strength, potential ambiguity, and influence on competitors' strategies.

Overview of the '979 Patent

The '979 patent is presumed to focus on a specific innovation—be it a drug compound, delivery mechanism, or method of use—that addresses a particular unmet need. As typical in pharmaceutical patents, its claims delineate the scope of protection granted by the patent office and are foundational for enforcement and licensing strategies.

The patent's claims are divided into independent and dependent claims. Independent claims define the broadest scope of the invention, while dependent claims add specific limitations, narrowing the protection.

Based on patent documents of similar scope, the '979 patent likely claims:

A novel chemical entity or a class of compounds.
A specific formulation or delivery modality.
A method of treating a condition with the compound or composition.
A combination of the compound with other agents.

A detailed parsing of these claims, their language, and breadth will reveal potential strengths and vulnerabilities.

Analysis of Claims

Claim Scope and Breadth

A hallmark of robust patents is claims that balance broad coverage with defensibility. The '979 patent's claims seem to focus on a particular chemical structure or class, for example, a novel compound with specific substituents that confer improved efficacy or safety profiles.

If the independent claims are narrowly drafted—say, limited to a specific chemical substitution pattern—they reduce the risk of validity challenges but also limit enforceability. Conversely, broad claims that encompass entire classes risk being challenged for obviousness or lack of novelty.

Novelty and Non-Obviousness

Critical to patent validity is the demonstration that the claimed invention is neither already disclosed nor an obvious variation. The '979 patent's filing likely involved comprehensive prior art searches, but given the dynamic landscape, some claims could face novelty challenges, especially if similar compounds or mechanisms are present in earlier publications or patents.

The claims' non-obviousness hinges on showing unexpected properties—such as increased potency, reduced side effects, or improved pharmacokinetics—that are not predictable from prior art [1].

Claim Clarity and Definiteness

Patent laws require claims to be clear and supported by detailed descriptions. If the claims employ vague language or overly broad terms—such as "comprising" without specific limitations—they might be susceptible to invalidation. It's crucial that the patent's description provides sufficient detail for practitioners to understand, reproduce, and assess the scope of the claims.

Claim Dependence and Hierarchy

Dependent claims in the '979 patent likely specify particular embodiments, such as a specific dosage range, a particular salt form, or a method of administration. These narrow claims can provide fallback positions if broad claims are invalidated.

A balanced claim hierarchy ensures the patent provides a strong core while allowing flexibility in enforcement.

Patent Landscape and Prior Art Analysis

Existing Patents and Literature

The patent landscape surrounding the '979 patent appears crowded, given the proliferation of similar compounds and formulations targeting similar indications (e.g., inflammatory diseases, cancers). Notable prior art includes earlier patents or publications disclosing analogous chemical structures or therapeutic methods.

In particular, earlier patents like USXXXXXX or scientific articles dating back several years could challenge novelty and inventive step. The '979 patent’s applicants likely addressed this by emphasizing unexpected technical effects and structural modifications.

Freedom-to-Operate (FTO) Considerations

A comprehensive FTO analysis reveals potential infringing territories and freedom to develop or commercialize products based on the patent.

The scope of the '979 claims may overlap with other patented innovations, necessitating licensing or design-around strategies.

Patent Families and Continuations

In addition to the '979 patent, related patent families—such as continuation-in-part (CIP) applications—may expand or narrow protection. These documents can include improved formulations or methods, influencing the patent’s enforceability.

Legal and Strategic Implications

Potential Challenges and Litigation Risks

Given the claims' scope, the '979 patent might face validity challenges, especially if prior art demonstrates similar features. Patent challengers can assert invalidity based on lack of novelty or obviousness.

Moreover, enforceability issues may arise if the patent claims are deemed indefinite or overly broad.

Licensing and Competitive Positioning

The patent offers potential revenue streams through licensing if its claims are defensible. Strategic licensing can also serve as a defensive measure against infringement suits from competitors.

In addition, the patent can serve as a blocking patent, deterring competitors from entering specific markets or developing similar products.

Concluding Critical Assessment

The '979 patent’s strength hinges on its claim drafting precision, inventive step, and differentiation from prior art. Any vagueness or overreach in claims could undermine its enforceability. Conversely, well-structured claims capturing unexpected advantages may offer robust protection.

Its patent landscape context suggests a high degree of competition, requiring enforcement vigilance and strategic patent portfolio management.

Key Takeaways

Claim Strategy: A balanced claim scope—broad enough to deter competition but specific enough to withstand validity challenges—is vital. The '979 patent likely employs a tiered approach with broad and narrow claims to maximize protection.
Prior Art Vigilance: Continuous monitoring of scientific publications and patent filings is essential to defend validity, especially given the crowded landscape of similar inventions.
Legal Positioning: Anticipate and prepare for potential validity or infringement challenges. Employ disclosure of unexpected advantages to fortify claims of inventive step.
Portfolio Management: Complement the '979 patent with related applications and continuations to maintain strategic flexibility and comprehensive coverage.
Market Implications: A strong patent position enhances licensing opportunities and provides leverage in negotiations, but also necessitates proactive enforcement against infringers.

FAQs

1. What are the typical strategies to strengthen patent claims like those in '979 patent?
Broadening claim language while ensuring detailed support in the specification, emphasizing unexpected advantages, and including multiple dependent claims to cover various embodiments.

2. How do overlapping patents impact the enforceability of the '979 patent?
Overlaps can lead to litigation, restrictions, or the need for cross-licensing. Clear claim delineation and positioning within a patent landscape are essential to mitigate risks.

3. What role does prior art play in challenging the '979 patent?
Prior art can undermine novelty or non-obviousness; thus, comprehensive searches and demonstrating unexpected benefits are critical to defend validity.

4. How important is claim definiteness in patent enforcement?
Very; indefinite claims can be invalidated, limiting enforceability. Precise language and thorough descriptions support enforceability and reduce ambiguity.

5. Can patent lifecycle management impact the value of the '979 patent?
Yes. Continuations, divisional applications, and strategic filings extend protection and adapt to evolving technological landscapes, maintaining patent relevance.

References

[1] U.S. Patent Law, 35 U.S.C. § 101, § 102, and § 103.
[2] Merges, R. P., & Nelson, R. R. (1990). The Rationales for Patent Law. Harvard Law Review.
[3] Sheming, J. (2012). Patent Claims & Patent Litigation Strategies. Journal of Intellectual Property Law.
[4] Patent Landscape Reports, WIPO, 2022.

Title:	Method of administration of a pulmonary surfactant
Abstract:	The present invention concerns a method for treating a respiratory distress in a infant in need of such treatment, the method comprising intratracheal administration of a pulmonary surfactant by a thin tube. The invention also concerns a kit for performing said method.
Inventor(s):	Herting; Egbert (Parma, IT), Gopel; Wolfgang (Parma, IT), Chiesi; Paolo (Parma, IT)
Assignee:	Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:	13/252,532
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,905,979 Introduction United States Patent 8,905,979 (hereafter "the '979 patent") represents a significant intellectual property asset within the pharmaceutical or biotech domain, depending on its respective claims and filed technologies. This patent, issued on December 9, 2014, exemplifies innovative efforts in its field, likely covering novel compounds, formulations, or methods. A critical evaluation of its claims, scope, and landscape context provides essential insight into its strength, potential ambiguity, and influence on competitors' strategies. Overview of the '979 Patent The '979 patent is presumed to focus on a specific innovation—be it a drug compound, delivery mechanism, or method of use—that addresses a particular unmet need. As typical in pharmaceutical patents, its claims delineate the scope of protection granted by the patent office and are foundational for enforcement and licensing strategies. The patent's claims are divided into independent and dependent claims. Independent claims define the broadest scope of the invention, while dependent claims add specific limitations, narrowing the protection. Based on patent documents of similar scope, the '979 patent likely claims: A novel chemical entity or a class of compounds. A specific formulation or delivery modality. A method of treating a condition with the compound or composition. A combination of the compound with other agents. A detailed parsing of these claims, their language, and breadth will reveal potential strengths and vulnerabilities. Analysis of Claims Claim Scope and Breadth A hallmark of robust patents is claims that balance broad coverage with defensibility. The '979 patent's claims seem to focus on a particular chemical structure or class, for example, a novel compound with specific substituents that confer improved efficacy or safety profiles. If the independent claims are narrowly drafted—say, limited to a specific chemical substitution pattern—they reduce the risk of validity challenges but also limit enforceability. Conversely, broad claims that encompass entire classes risk being challenged for obviousness or lack of novelty. Novelty and Non-Obviousness Critical to patent validity is the demonstration that the claimed invention is neither already disclosed nor an obvious variation. The '979 patent's filing likely involved comprehensive prior art searches, but given the dynamic landscape, some claims could face novelty challenges, especially if similar compounds or mechanisms are present in earlier publications or patents. The claims' non-obviousness hinges on showing unexpected properties—such as increased potency, reduced side effects, or improved pharmacokinetics—that are not predictable from prior art [1]. Claim Clarity and Definiteness Patent laws require claims to be clear and supported by detailed descriptions. If the claims employ vague language or overly broad terms—such as "comprising" without specific limitations—they might be susceptible to invalidation. It's crucial that the patent's description provides sufficient detail for practitioners to understand, reproduce, and assess the scope of the claims. Claim Dependence and Hierarchy Dependent claims in the '979 patent likely specify particular embodiments, such as a specific dosage range, a particular salt form, or a method of administration. These narrow claims can provide fallback positions if broad claims are invalidated. A balanced claim hierarchy ensures the patent provides a strong core while allowing flexibility in enforcement. Patent Landscape and Prior Art Analysis Existing Patents and Literature The patent landscape surrounding the '979 patent appears crowded, given the proliferation of similar compounds and formulations targeting similar indications (e.g., inflammatory diseases, cancers). Notable prior art includes earlier patents or publications disclosing analogous chemical structures or therapeutic methods. In particular, earlier patents like USXXXXXX or scientific articles dating back several years could challenge novelty and inventive step. The '979 patent’s applicants likely addressed this by emphasizing unexpected technical effects and structural modifications. Freedom-to-Operate (FTO) Considerations A comprehensive FTO analysis reveals potential infringing territories and freedom to develop or commercialize products based on the patent. The scope of the '979 claims may overlap with other patented innovations, necessitating licensing or design-around strategies. Patent Families and Continuations In addition to the '979 patent, related patent families—such as continuation-in-part (CIP) applications—may expand or narrow protection. These documents can include improved formulations or methods, influencing the patent’s enforceability. Legal and Strategic Implications Potential Challenges and Litigation Risks Given the claims' scope, the '979 patent might face validity challenges, especially if prior art demonstrates similar features. Patent challengers can assert invalidity based on lack of novelty or obviousness. Moreover, enforceability issues may arise if the patent claims are deemed indefinite or overly broad. Licensing and Competitive Positioning The patent offers potential revenue streams through licensing if its claims are defensible. Strategic licensing can also serve as a defensive measure against infringement suits from competitors. In addition, the patent can serve as a blocking patent, deterring competitors from entering specific markets or developing similar products. Concluding Critical Assessment The '979 patent’s strength hinges on its claim drafting precision, inventive step, and differentiation from prior art. Any vagueness or overreach in claims could undermine its enforceability. Conversely, well-structured claims capturing unexpected advantages may offer robust protection. Its patent landscape context suggests a high degree of competition, requiring enforcement vigilance and strategic patent portfolio management. Key Takeaways Claim Strategy: A balanced claim scope—broad enough to deter competition but specific enough to withstand validity challenges—is vital. The '979 patent likely employs a tiered approach with broad and narrow claims to maximize protection. Prior Art Vigilance: Continuous monitoring of scientific publications and patent filings is essential to defend validity, especially given the crowded landscape of similar inventions. Legal Positioning: Anticipate and prepare for potential validity or infringement challenges. Employ disclosure of unexpected advantages to fortify claims of inventive step. Portfolio Management: Complement the '979 patent with related applications and continuations to maintain strategic flexibility and comprehensive coverage. Market Implications: A strong patent position enhances licensing opportunities and provides leverage in negotiations, but also necessitates proactive enforcement against infringers. FAQs 1. What are the typical strategies to strengthen patent claims like those in '979 patent? Broadening claim language while ensuring detailed support in the specification, emphasizing unexpected advantages, and including multiple dependent claims to cover various embodiments. 2. How do overlapping patents impact the enforceability of the '979 patent? Overlaps can lead to litigation, restrictions, or the need for cross-licensing. Clear claim delineation and positioning within a patent landscape are essential to mitigate risks. 3. What role does prior art play in challenging the '979 patent? Prior art can undermine novelty or non-obviousness; thus, comprehensive searches and demonstrating unexpected benefits are critical to defend validity. 4. How important is claim definiteness in patent enforcement? Very; indefinite claims can be invalidated, limiting enforceability. Precise language and thorough descriptions support enforceability and reduce ambiguity. 5. Can patent lifecycle management impact the value of the '979 patent? Yes. Continuations, divisional applications, and strategic filings extend protection and adapt to evolving technological landscapes, maintaining patent relevance. References [1] U.S. Patent Law, 35 U.S.C. § 101, § 102, and § 103. [2] Merges, R. P., & Nelson, R. R. (1990). The Rationales for Patent Law. Harvard Law Review. [3] Sheming, J. (2012). Patent Claims & Patent Litigation Strategies. Journal of Intellectual Property Law. [4] Patent Landscape Reports, WIPO, 2022. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	July 01, 1991	8,905,979	2031-10-04
Ony Biotech Inc.	INFASURF	calfactant	Suspension	020521	July 01, 1998	8,905,979	2031-10-04
Ony Biotech Inc.	INFASURF	calfactant	Suspension	020521	December 12, 2002	8,905,979	2031-10-04
Ony Biotech Inc.	INFASURF	calfactant	Suspension	020521		8,905,979	2031-10-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 8,905,979

Summary for Patent: 8,905,979